AI Risk Prediction: Moving From Modeled Value to Realized ROI

• A systematic review of 48 economic evaluations (50 datasets; 31 cost-utility analyses) reports that 89% of AI-empowered precision medicine (AI-PM) interventions were cost-saving or cost-effective in base-case analyses.

• Despite the high success rate, the economic margins are thin: the median incremental cost was −$26 per patient, with a median QALY gain of 0.006 and a median Net Monetary Benefit (NMB) of $212 (at 1× per-capita GDP willingness-to-pay).

• For inpatient pharmacy, this signals that "plug-and-play" value is a myth; realized ROI depends entirely on operational scale and whether predictions trigger timely, pharmacist-led interventions.

• Pharmacy directors are inundated with proposals for AI tools (sepsis alerts, genomic matching, opioid risk) that promise high returns; however, the literature reflects "systematic optimism," often driven by study design rather than real-world performance.

• Modeled value frequently evaporates in practice because evaluations rarely account for "integration tax" (interface construction, maintenance, training) or the reality of clinician non-compliance with alerts.

• Adoption decisions must shift from purchasing software to funding stewardship: without a budgeted "human-in-the-loop" workflow to validate and act on data, the theoretical $212 per-patient benefit will not materialize.

• Researchers conducted a systematic search (2013–2023) identifying 48 economic evaluations. They isolated 31 cost-utility analyses to standardize comparisons of costs, QALYs, and NMB across different healthcare systems, inflating all figures to 2023 USD.

• They assessed risk of bias using the ECOBIAS checklist and coded specific implementation attributes, such as whether the study modeled clinician non-compliance or adaptability across settings.

• A mixed-effects regression with LASSO feature selection was used to isolate which factors—such as funding source, AI unit cost, or study perspective—truly drove the reported economic value.

• While 89% of studies claimed cost-effectiveness, results were highly heterogeneous: Risk-prediction tools (e.g., sepsis, AKI) showed a significantly higher median NMB ($687) than digital diagnostics ($92), but also displayed much wider variance, indicating high implementation risk.

• Regression analysis identified "AI unit cost" as a significant predictor of value (+$2.94 NMB per $1 increase), suggesting that higher-cost, complex tools may deliver better returns than generic algorithms.

• Potential biases inflated results: private funding was associated with higher reported NMB (+$248 point estimate), while modeling real-world clinician compliance lowered the reported value substantially (−$1,200 point estimate). Although these specific associations did not reach statistical significance, they signal a "hype tax" in vendor-sponsored data.

• Implementation realities were largely ignored: only ~12% of studies modeled clinician compliance, and ~63% failed to clarify if the tool was adaptable to new hospital settings.

• Treat vendor ROI claims with skepticism: the median QALY gain of 0.006 indicates that AI-PM generates value through marginal process efficiencies, not miraculous clinical rescues.

• Prioritize "Risk Prediction" workflows: This domain offers the highest potential NMB ($687) for pharmacy but requires the heaviest investment in staff response; success depends on moving pharmacists from reactive verification to proactive risk triage.

• Scrutinize the "Compliance Gap": When evaluating a tool, ask if the ROI model assumes 100% adoption. If it does, discount the value significantly to account for alert fatigue and lack of trust.

• Require "Silent Pilots": Mandate a local, silent validation phase to measure concordance and false-positive rates before signing a contract; widely reported "adaptability gaps" mean algorithms may fail when moved to your specific patient population.

Strengths:

• This is the first comprehensive quantitative synthesis (48 evaluations) to normalize AI-PM costs to 2023 USD, enabling valid cross-border comparison. The use of mixed-effects regression provides a rigorous method for isolating the impact of study design biases (like funding source) from the actual technological value.

Limitations:

• The analysis was restricted to English-language reports and cost-utility analyses. The high residual variance in the regression models suggests that unmeasured local factors heavily influence value. Crucially, the widespread underreporting of implementation costs means the literature likely overestimates the true net benefit for hospital budgets.

AI-PM offers a verifiable but heterogeneous economic signal, particularly in risk prediction. Pursue narrow, governance-backed pilots with transparent costing and compliance-aware workflows; do not assume vendor-reported NMBs translate directly to local ROI without internal validation.